“The greatest need we have today in the human cancer problem, except for universal care, is a method for detecting cancer before there are any clinical signs or symptoms.”
Sidney Farber, M.D.
Father of modern chemotherapy
pioneering the detection of early cancer
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Incubated within Flagship Pioneering for three years before launching in 2021, Harbinger combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test.
A harbinger is a “forerunner, that which precedes and gives notice of the coming of another.” We not only are working to identify the harbinger – the biological programs present in the earliest forms of cancer – but seek to be the harbinger, to be the forerunner which will usher in the future of healthcare.
At Harbinger, we intend to lead in shaping this future – creating a proactive paradigm so that people can live cancer-free for longer, adding years to life and life to years. We envision a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
Our answer to the problem of late cancer detection and unacceptable patient prognoses starts with our proprietary solutions for the future of cancer pre-emption. Beginning with blood-based tests, we will enable cancer detection before it is visible. By identifying biological programs rooted in cancer's origins, we can enable identification of early stage and pre-disease. Through this new pathway for cancer diagnosis and early therapeutic interventions, Harbinger Health has the potential to fundamentally change cancer care, for everyone.
Prof. Franziska Michor, Ph.D.
Franziska Michor, Ph.D. serves as a Scientific Advisor at Harbinger Health and is a Professor of Computational Biology in the Department of Data Science at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cell and Regenerative Biology at Harvard University.
Dr. Michor obtained her undergraduate training in mathematics and molecular biology from the University of Vienna, Austria, and her PhD from the Department of Organismic and Evolutionary Biology at Harvard University. Afterwards, she was awarded a fellowship from the Harvard Society of Fellows. From 2007 until 2010, she was an Assistant Professor in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Michor is the director of the Dana-Farber Cancer Institute Center for Cancer Evolution and co-directs the Cancer Immunological Data Commons. She has been the recipient of the Theodosius Dobzhansky Prize of the Society for the Study of Evolution, the Alice Hamilton Award, the Vilcek Prize for Creative Promise in Biomedical Science, the 36th Annual AACR Award for Outstanding Achievement in Cancer Research, and others.
Dr. Michor’s laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy, and emergence of resistance.
our leadership team
our board of directors
Director, Social & Behavioral Sciences, Community Engagement
Operation Warp Speed
Professor, Department of Gastrointestical Medical Oncology
Chair Department of Investigational Cancer Therapeutics
Chief Quality Officer
Board member, Kaiser Foundation